Literature DB >> 17178846

Tumor necrosis factor-alpha is a potent endogenous mutagen that promotes cellular transformation.

Bin Yan1, Huili Wang, Zahid N Rabbani, Yulin Zhao, Wenrong Li, Yuqing Yuan, Fang Li, Mark W Dewhirst, Chuan-Yuan Li.   

Abstract

Tumor necrosis factor-alpha (TNF-alpha) is an important inflammation cytokine without known direct effect on DNA. In this study, we found that TNF-alpha can cause DNA damages through reactive oxygen species. The mutagenic effect of TNF-alpha is comparable with that of ionizing radiation. TNF-alpha treatment in cultured cells resulted in increased gene mutations, gene amplification, micronuclei formation, and chromosomal instability. Antioxidants significantly reduced TNF-alpha-induced genetic damage. TNF-alpha also induced oxidative stress and nucleotide damages in mouse tissues in vivo. Moreover, TNF-alpha treatment alone led to increased malignant transformation of mouse embryo fibroblasts, which could be partially suppressed by antioxidants. As TNF-alpha is involved in chronic inflammatory diseases, such as chronic hepatitis, ulcerative colitis, and chronic skin ulcers, and these diseases predispose the patients to cancer development, our results suggest a novel pathway through which TNF-alpha promotes cancer development through induction of gene mutations, in addition to the previously reported mechanisms, in which nuclear factor-kappaB activation was implicated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178846     DOI: 10.1158/0008-5472.CAN-06-2540

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  TNFα enhances cancer stem cell-like phenotype via Notch-Hes1 activation in oral squamous cell carcinoma cells.

Authors:  Sung Hee Lee; Hannah S Hong; Zi Xiao Liu; Reuben H Kim; Mo K Kang; No-Hee Park; Ki-Hyuk Shin
Journal:  Biochem Biophys Res Commun       Date:  2012-06-20       Impact factor: 3.575

2.  Enterococcus faecalis induces aneuploidy and tetraploidy in colonic epithelial cells through a bystander effect.

Authors:  Xingmin Wang; Toby D Allen; Randal J May; Stanley Lightfoot; Courtney W Houchen; Mark M Huycke
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

Review 3.  Oxidative stress-associated protein tyrosine kinases and phosphatases in Fanconi anemia.

Authors:  Jie Li; Qishen Pang
Journal:  Antioxid Redox Signal       Date:  2014-03-11       Impact factor: 8.401

4.  Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus.

Authors:  Olga Chemnitzer; Katharina Götzel; Luisa Maurer; Arne Dietrich; Uwe Eichfeld; Orestis Lyros; Boris Jansen-Winkeln; Albrecht Hoffmeister; Ines Gockel; René Thieme
Journal:  Dig Dis Sci       Date:  2017-10-30       Impact factor: 3.199

Review 5.  Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease?

Authors:  Diana Crossley; Robert Stockley; Elizabeth Sapey
Journal:  Drugs Aging       Date:  2019-09       Impact factor: 3.923

Review 6.  Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.

Authors:  Masakazu Yashiro
Journal:  Dig Dis Sci       Date:  2015-04-04       Impact factor: 3.199

7.  Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases.

Authors:  Marvin B Brooks
Journal:  Oncologist       Date:  2013

8.  Glucans from the edible mushroom Pleurotus pulmonarius inhibit colitis-associated colon carcinogenesis in mice.

Authors:  Iris Lavi; Lili Nimri; Dana Levinson; Irena Peri; Yitzhak Hadar; Betty Schwartz
Journal:  J Gastroenterol       Date:  2011-12-21       Impact factor: 7.527

Review 9.  Tumor necrosis factor and cancer, buddies or foes?

Authors:  Xia Wang; Yong Lin
Journal:  Acta Pharmacol Sin       Date:  2008-11       Impact factor: 6.150

Review 10.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Authors:  Keren Levanon; Christopher Crum; Ronny Drapkin
Journal:  J Clin Oncol       Date:  2008-10-14       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.